What is Seraxis?
Founded in 2013 and operating from Germantown, Maryland, Seraxis is a privately held biotechnology company dedicated to addressing insulin-dependent diabetes through its proprietary cell line and manufacturing technology. The company specializes in producing transplant-ready human pancreatic islets, aiming to offer a viable treatment for patients. Seraxis has also developed SeraGraft, a device designed to shield these vital human pancreas cells from immune system rejection, a critical hurdle in transplantation.
How much funding has Seraxis raised?
Seraxis has raised a total of $40.1M across 2 funding rounds:
Debt
$87K
Series C
$40M
Debt (2021): $87K with participation from PPP
Series C (2021): $40M led by Polaris Partners, JDRF T1D Fund, Frazier Healthcare Partners, and Eli Lilly and Company
Key Investors in Seraxis
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth.
JDRF T1D Fund
The T1D Fund is a scaled venture impact fund dedicated to accelerating treatments, prevention, and cures for the 9 million people living with Type 1 Diabetes (T1D). With over $200 million in assets under management and a portfolio of 25+ active companies, the fund strategically invests in innovative therapies aimed at disease modification and potential cures.
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent investment firm with a deep focus on the healthcare industry, known for its strategic backing of companies aiming to advance medical treatments and technologies. Their involvement suggests a strong belief in Seraxis's potential to disrupt the diabetes treatment landscape.
What's next for Seraxis?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Seraxis for accelerated growth and the scaling of its innovative therapeutic solutions. This capital infusion is expected to fuel further research and development, clinical trials, and the expansion of manufacturing capabilities. The company's focus on a critical unmet medical need in diabetes treatment, combined with its unique technological approach, suggests a trajectory towards significant clinical and commercial milestones.
See full Seraxis company page
